Navigation Links
Bioject Enters Into Agreement With Fondaco PTE LTD For Distribution Of Full Line Of Needle Free Injection Devices In Asia

TIGARD, Ore., Oct. 23, 2013 /PRNewswire/ -- Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer and manufacturer of needle-free injection technology, today announced that it has entered into a distribution agreement with Fondaco PTE, LTD, a premier medical supplies company based in Singapore. Under the terms of this agreement, Fondaco will be the exclusive distributor of Bioject's commercial needle-free injection products in Singapore, Indonesia, and Malaysia.

Products positioned for distribution through this agreement include the full portfolio of Bioject technologies including the Biojector® 2000 needle-free injection system and theBioject® ZetaJet™ portable injector.  In September 2013, Bioject also announced an international distribution agreement with iHealthnet LLC for distribution of Bioject products in markets including South Asia, India and the Middle East.

"We have seen significant demand for advanced needle-free technologies in global markets including Asia in recent years. Through collaboration with established industry leaders such as Fondaco, we will be ideally positioned to expand our product marketing focus in this region in the years ahead.  Together we have the full range of expertise and insight to bring the significant advantages of needle-free drug delivery to millions more patients in the years ahead," said Mark Logomasini, President and CEO of Bioject.

The global injectable drug delivery technologies market was valued at $22.5 billion in 2012, and is expected to reach $43.3 billion by 2017.  Recent reports indicate that the market for injectable technologies is positioned to grow rapidly in Asia in the coming decade, based in part on expanding access to healthcare services and the growing number of patients in emerging markets affected by diabetes and other diseases that involve treatment with injectable drugs.

Bioject's advanced needle-free technology works by forcing liquid medication at high speed through a tiny orifice held against the skin. The diameter of the orifice is smaller than the diameter of a human hair. This creates an ultra-fine stream of medicine able to penetrate skin without use of a needle.  Bioject's technology is available for use with a wide range of injectable drugs and has the ability to deliver medicine at a range of depths and injection volumes. For instance, the Biojector 2000 can deliver intramuscular or subcutaneous injections up to 1 mL in volume. Bioject technologies also include auto-disable features that can prevent inappropriate reuse of syringes.

"By combining Bioject's outstanding technology and products with our established marketing and distribution network and our extensive experience in meeting the needs of pharma and life sciences companies in Asia, this collaboration positions us to rapidly expand market penetration for Bioject products throughout Singapore, Malaysia and Indonesia.  Working together we will also play an important role in helping more life science companies as well as patients and clinicians in these markets to recognize the improved convenience, safety and comfort that Bioject needle-free drug delivery offers," said Jane Fonda, Chief Executive Officer of Fondaco.

About Bioject Medical Technologies Inc.

Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a developer and manufacturer of needle-free injection therapy systems (NFITS). To meet global demand for needle free injection technologies, Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and government organizations. 

Readers and potential investors are cautioned that an investment in the Bioject's securities involve an EXTREMELY high degree of risk. Such risks include, without limitation, the risk that the distribution agreement will not be successful due to the time required in obtaining government clearances and the risk that the Company may be unable to comply with the extensive government regulations applicable to the international business. Bioject (OTC Pink: BJCT) trades on the OTC Pink tier of the OTC market.  Investors can find Real-Time quotes and market information for the Company on   

For more information about Bioject, visit

SOURCE Bioject Medical Technologies Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Therapeutic Vaccine for Hepatitis C Enters Phase I Clinical Trial
2. IceCure Enters a New High-Potential Market: The company received $100K-order for cryoablation consoles and probes to be used in a clinical study for the treatment of lung cancer
3. Gliknik Enters Into Licensing Agreement With Pfizer For Drug Candidate Targeting Autoimmune Diseases
4. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
5. JHP Pharmaceuticals Enters Agreement to Produce Unique Late Stage Ophthalmic Product
6. HedgePath Pharmaceuticals Enters into Key Collaboration with Mayne Pharma
7. Simcere Pharmaceutical Group Enters Into Definitive Merger Agreement for Going Private Transaction
8. Piramal Imaging Provides Comments in Response to the Centers for Medicare and Medicaid Services (CMS) Proposed Coverage Decision for Beta-Amyloid Positron Emission Tomography (PET)
9. Large National Network of Ambulatory Surgical Centers Doubles Order of STREAMWAY Systems
10. Breckenridge Enters Into Agreement to Acquire Certain Cypress Assets from Pernix Therapeutics
11. Life Technologies Enters into an Exclusive License and Supply Agreement for Dynabeads
Post Your Comments:
(Date:11/24/2015)... Connecticut , November 24, 2015 ... of Acadiana has entered into a multi-year agreement ... imaging centers. This investment will provide the Breast Center ... --> Sectra (STO: SECT B) announces that ... agreement to deploy Breast Imaging PACS in its ...
(Date:11/24/2015)... , Nov. 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ... its Board of Directors has declared a special 1 percent ... dividend is payable December 14, 2015, to shareholders of record ... form of additional shares of common stock. ... Board is a strong endorsement of our confidence in Ascendant,s ...
(Date:11/24/2015)... -- iRhythm Technologies, Inc. , a leading digital health care ... will participate in the 27th Annual Piper Jaffray Healthcare Conference at ... . Kevin King , Chief Executive Officer of ... 8:50am ET. --> --> ... . --> iRhythm is a privately held ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... In an article ... variables that determine which patients are or are not eligible for bariatric surgery. The ... BMI over 40, are more than 100 pounds overweight, or have a BMI of ...
(Date:11/24/2015)... ... 24, 2015 , ... It takes only three to five seconds to make ... the first impression be positive and reflects business values. If a client starts with ... want to return. They will also share their thoughts about a business with others, ...
(Date:11/24/2015)... ... 24, 2015 , ... Cancer patients, survivors, caregivers, family members ... live taping of the next CURE Connections® video series on Saturday, ... Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the ... study designed to yield insights into how to detect and treat pancreatic cancer (PC). ... cancer from small, non-coding RNA molecules (ncRNA), genetic material that is present in the ...
(Date:11/24/2015)... ... 2015 , ... Sir Grout of Baltimore is proud to ... award recognizes good companies for excellence in service and a commitment to the ... surface restoration company earned this recognition after a thorough review by the acclaimed ...
Breaking Medicine News(10 mins):